Sharing an advertisement, several AAP leaders attacked the Centre, claiming a 'vaccination scam' as private parties continue to offer COVID-19 vaccines
By siliconindia | Monday, 24 May 2021, 07:06 Hrs Indian vaccine innovator Bharat Biotech International (BBIL), which developed the indigenous COVID-19 vaccine with Indian Council of Medical Research (ICMR) and the National Institute of Virology, will begin clinical trials of the vaccine on pediatrics from June 1. The Hyderabad headquartered vaccine maker has recently received approvals from the drug regulator to carry out paediatric trials of the vaccine. “It will be a trial on children aged 2-18 years,” stated Raches Ella, Bharat Bio’s head-business development and international advocacy, addressing a FICCI Ladies Organisation (FLO) meeting in Hyderabad on Saturday. “Kids vaccine trials of Bharat Biotech may get the license in the third quarter of this year.”
ICMR ready to offer Covaxin know-how to other firms
May 07, 2021
The Indian Council of Medical Research (ICMR) is willing to share the know-how to produce the indigenously-developed Covid-19 vaccine, Covaxin, with any company as the contract with co-developer Bharat Biotech is not close-ended.
Currently, Bharat Biotech has the sole licence to manufacture Covaxin, which it developed in collaboration with scientists from ICMR’s Pune-based National Institute of Virology (NIV).
An official involved with the developments told
BusinessLine that the terms and conditions agreed upon while transferring the Covid-19 vaccine technology was that Bharat Bio will pay the ICMR 5 per cent royalty on the net sales of Covaxin.